Chris Murphy actually said...

It took us a long time to educate both providers and patients about chemical generics.

If we are successful in getting this pathway to biosimilars moving then my fear is with a product sitting on the market that could cost 30 p...

We can do all of this work on trying to make sure that we approve biosimilars, but if they're not actually getting prescribed, if we aren't ...

This increased cost is born by our healthcare system as a whole, but more specifically by patients as more and more insurance companies plac...